The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

EP 092     (Z)-7-[(1R,2R,3R,4S)-3-[C- methyl-N...

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

High impact information on EP 092

  • An analogue of prostaglandin H2, 11,9 epoxymethano-prostaglandin H2, which directly stimulates thromboxane receptors, and EP 092, which is a competitive thromboxane A2 receptor antagonist, were used to investigate changes at platelet thromboxane receptor level in these groups [1].
  • Acute administration of the TxA2 synthesis inhibitor, UK-38,485, and a TxA2 receptor antagonist, EP-092, to rats given CBGG did not affect GFR or RPF [2].
  • 1. The inhibitory effect of a selective prostaglandin H2 (PGH2)/thromboxane A2 receptor antagonist, EP 092, on platelet aggregatory responses in whole blood ex vivo (guinea-pig: Rhesus monkey) and intravascular aggregation in vivo (rabbit) has been investigated [3].
  • 4. The inhibitory activity demonstrated by EP 092 against collagen-induced aggregation of Rhesus monkey whole blood ex vivo was not accompanied by any significant reduction in thromboxane A2 formation except at the highest dose tested (10 mg kg-1) [3].
  • The inhibitory effects of three prostanoid analogues, EP 045, EP 092 and pinane thromboxane A2 (PTA2), on the aggregation of human platelets in vitro have been investigated [4].

Analytical, diagnostic and therapeutic context of EP 092


  1. Increased platelet thromboxane receptor sensitivity in diabetic patients with proliferative retinopathy. Collier, A., Tymkewycz, P., Armstrong, R., Young, R.J., Jones, R.L., Clarke, B.F. Diabetologia (1986) [Pubmed]
  2. Immune complex effects on glomerular eicosanoid production and renal hemodynamics. Rahman, M.A., Emancipator, S.N., Dunn, M.J. Kidney Int. (1987) [Pubmed]
  3. Inhibitory effect of a selective thromboxane A2 receptor antagonist, EP 092, on platelet aggregation in whole blood ex vivo and in vivo. Booth, R.F., Honey, A.C., Lad, N., Tuffin, D.P., Wade, P.J. Br. J. Pharmacol. (1989) [Pubmed]
  4. Competitive antagonism at thromboxane receptors in human platelets. Armstrong, R.A., Jones, R.L., Peesapati, V., Will, S.G., Wilson, N.H. Br. J. Pharmacol. (1985) [Pubmed]
WikiGenes - Universities